NovaBridge Biosciences (FRA:0VY) EBIT: €-80.96 Mil (TTM As of Dec. 2025)

What is NovaBridge Biosciences EBIT?

NovaBridge Biosciences FRA:0VY -1.43% 30 EBIT is €-80.96 Mil as of Dec. 2025. GuruFocus rates FRA:0VY with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

NovaBridge Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €-62.26 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-80.96 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NovaBridge Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 was -592.25%. NovaBridge Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -9,550.45%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NovaBridge Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 406.95%.

NovaBridge Biosciences (FRA:0VY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NovaBridge Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-249.028 * ( 1 - 0% )	/	( (38.772	+	45.324)	/ 2 )
=	-249.028	/	42.048
=	-592.25 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	236.353	-	12.967	-	( 194.489	-	max(0, 13.71	-	198.324	+	194.489	))
=	38.772

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	222.486	-	14.367	-	( 180.059	-	max(0, 22.967	-	185.762	+	180.059	))
=	45.324

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

NovaBridge Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-249.028	/	( ( (2.697 + max(-9.921, 0))	+	(2.518 + max(-18.034, 0)) )	/	2 )
=	-249.028	/	( ( 2.697	+	2.518 )	/	2 )
=	-249.028	/	2.6075
=	-9,550.45 %

where Working Capital is:

	Working Capital		(Q: Sep. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.046)	-	(12.967	+	0	+	0)
=	-9.921

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.172)	-	(14.367	+	0	+	7.839)
=	-18.034

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NovaBridge Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-80.955	/	-19.893
	=	406.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovaBridge Biosciences EBIT Related Terms

NovaBridge Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for NovaBridge Biosciences's EBIT can be seen below:

NovaBridge Biosciences EBIT Chart

NovaBridge Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-324.16

-50.11

-44.91

-49.11

-80.51

NovaBridge Biosciences Quarterly Data
	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
EBIT	Get a 7-Day Free Trial															-12.77	-4.87	-6.17	-7.66	-62.26

FRA:0VY vs ELTX, CNTN, INDP: EBIT Comparison

For the Biotechnology subindustry, NovaBridge Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovaBridge Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBridge Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NovaBridge Biosciences's EV-to-EBIT falls into.

Save Embed

30GF Score

NovaBridge Biosciences FRA:0VY

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NovaBridge Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-80.96 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-80.96 Mil mean?

NovaBridge Biosciences (FRA:0VY) has a EBIT of €-80.96 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NovaBridge Biosciences.

Is NovaBridge Biosciences' EBIT too high?

NovaBridge Biosciences' current EBIT is €-80.96 Mil. Overall, NovaBridge Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does NovaBridge Biosciences' EBIT compare to ELTX and CNTN?

NovaBridge Biosciences' EBIT of €-80.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NovaBridge Biosciences. NovaBridge Biosciences's current EBIT is €-80.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NovaBridge Biosciences stock overvalued right now?

NovaBridge Biosciences (FRA:0VY) has a current EBIT of €-80.96 Mil. The current EBIT is €-80.96 Mil. NovaBridge Biosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For NovaBridge Biosciences (FRA:0VY), the current EBIT is €-80.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NovaBridge Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies ELTX CNTN INDP NGEN KPTI IMUX KROS RNA RNAC ARCT VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges NBP:USA

Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website https://www.novabridge.com

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.

30GF Score

Get the complete analysis for FRA:0VY

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.38

Price

View FRA:0VY Analysis

See EBIT data for all stocks →